Renaissance Capital logo

GH Research Priced, Nasdaq: GHRS

Phase 2 biotech developing DMT-based therapies for depression.

Industry: Health Care

Latest Trade: $10.66 -0.05 (-0.5%)

First Day Return: +20.3%

Return from IPO: -33.1%

Industry: Health Care

We are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Our initial focus is on developing our novel and proprietary 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Our portfolio currently includes GH001, our proprietary inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, our proprietary injectable 5-MeO-DMT product candidate. We have completed a Phase 1 healthy volunteer clinical trial, in which administration of GH001 via inhalation was observed to be well tolerated at the investigated single dose levels and in an individualized dosing regimen with intra-subject dose escalation within a single day. GH001 is currently being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. Based on observed clinical activity, we believe that administration of a single dose of GH001 has the potential to induce ultra-rapid remissions as measured by the Montgomery-Åsberg Depression Rating Scale, or MADRS, in certain patients, driven by the ultra-rapid onset of psychoactive effects (commonly within seconds) and an intense and short-lived (commonly five to 30 minutes) initial psychoactive experience.
more less
IPO Data
IPO File Date 06/04/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.0
Deal Size ($mm) $160
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/24/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.0
Deal Size ($mm) $160
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
TD Cowen
Stifel
more
Company Data
Headquarters Dublin, Ireland
Founded 2018
Employees 8
Website www.ghres.com

GH Research (GHRS) Performance